-
Board Certification
American Board of Internal MedicineAmerican Board of Internal Medicine (Sub: Hematology)American Board of Internal Medicine (Sub: Medical Oncology)Patient Rating
4.9 /5( out of 56 reviews )The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.
The scale on which responses are measured is 1 to 5 with 5 being the best score.
Patient Comments
Patient comments are gathered from our patient experience survey and displayed in their entirety.
Patients are de-identified for confidentiality and patient privacy.October 29, 2024HUNTSMAN CANCER CENTERDr Chalmers is a calming person. I feel as if I have all the time in the world with her.
September 28, 2024HUNTSMAN CANCER CENTERVery positive and caring. I could tell she was very knowledgeable. Made me feel comfortable Told me of the treatment to follow
September 13, 2024HUNTSMAN CANCER CENTERShe was very kind, and showed me that she was willing to help me anyway she could
September 12, 2024HUNTSMAN CANCER CENTERWith 8 years of experience with Dr. Chalmers I highly recommend her. My medical attention was always great. My cancer is a great concern but with the confident medical treatment I am doing well.
July 31, 2024HUNTSMAN CANCER CENTERDr. Chalmers has been with me for over 8 years of fighting these rare tumors. She is always caring and knowledgable.
July 30, 2024HUNTSMAN CANCER CENTERAlways kind and caring - excellent care provider.
July 18, 2024HUNTSMAN CANCER CENTERSHE A SUPER PERSON AND SUPER DOCTOR
July 17, 2024HUNTSMAN CANCER CENTERI have been coming to Huntsman for 10 years for treatments, have seen many very good Dr.'s. But without a doubt, Dr. Chalmers is one of the BEST! She treats me not only as her patient first, but also cares about me a person!
June 04, 2024HUNTSMAN CANCER CENTERIf you need a cancer doctor, Doctor Chalmers is peerless!
-
Board Certification and Academic Information
Academic Departments Internal Medicine -Primary Academic Divisions Oncology
Board Certification American Board of Internal MedicineAmerican Board of Internal Medicine (Sub: Hematology)American Board of Internal Medicine (Sub: Medical Oncology)Education history
Fellowship Hematology and Medical Oncology - Rush University Medical Center Fellow Residency Internal Medicine - Rush University Medical Center Resident Professional Medical Medicine - Drexel University College of Medicine M.D. Undergraduate Dartmouth College B.A. Selected Publications
Journal Article
- Puri S, Malani R, Chalmers A, Kerrigan K, Patel SB, Monynahan K, Cannon L, Blouw B, Akerley W (2023). Keeping a track on leptomeningeal disease in non-small cell lung cancer: A single-institution experience with CNSide(TM). Neurooncol Adv, 6(1), vdad150. (Read full article)
- Kerrigan K, Patel SB, Haaland B, Ose D, Weinberg Chalmers A, Haydell T, Meropol NJ, Akerley W (2020). Prognostic Significance of Patient-Reported Outcomes in Cancer. JCO Oncol Pract, 16(4), e313-e323. (Read full article)
- Chalmers AW, Patel S, Boucher K, Cannon L, Esplin M, Luckart J, Graves N, Van Duren T, Akerley W (2019). Phase I Trial of Targeted EGFR or ALK Therapy with Ipilimumab in Metastatic NSCLC with Long-Term Follow-Up. Target Oncol, 14(4), 417-421. (Read full article)
- Chalmers A, Cannon L, Akerley W (2018). Adverse Event Management in Patients with BRAF V600E-Mutant Non-Small Cell Lung Cancer Treated with Dabrafenib plus Trametinib. Oncologist, 24(7), 963-972. (Read full article)
Editorial
- Chalmers AW, Patel SB, Akerley W (2018). Immunotherapy after chemoradiotherapy in stage III non-small cell lung cancer: a new standard of care? J Thorac Dis, 10(3), 1198-1200. (Read full article)
Letter
- Chalmers A, Akerley W (2017). Retrospective, Multi-Institutional Analysis of Sequential Treatment of Brain Metastases in Treatment-Naïve, Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer Should Not Define the Standard of Practice. [Letter to the editor]. J Clin Oncol, 35(20), 2340. (Read full article)
-
News & Podcasts
Huntsman Cancer Institute News
-
Clinical Trials
- Randomized Phase 2 Study of Cabozantinib, Ipilimumab, and Nivolumab in Patients with Soft Tissue Sarcoma
- Randomized Phase 2 Study of Cabozantinib, Ipilimumab, and Nivolumab in Patients with Soft Tissue Sarcoma
- Randomized Phase 2 Study of Cabozantinib, Ipilimumab, and Nivolumab in Patients with Soft Tissue Sarcoma
- Randomized Phase 2 Study of Cabozantinib, Ipilimumab, and Nivolumab in Patients with Soft Tissue Sarcoma
- Randomized Phase 2 Study of Cabozantinib, Ipilimumab, and Nivolumab in Patients with Soft Tissue Sarcoma
- Randomized Phase 2 Study of Cabozantinib, Ipilimumab, and Nivolumab in Patients with Soft Tissue Sarcoma
- Randomized Phase 2 Study of Cabozantinib, Ipilimumab, and Nivolumab in Patients with Soft Tissue Sarcoma
- Randomized Phase 2 Study of Cabozantinib, Ipilimumab, and Nivolumab in Patients with Soft Tissue Sarcoma
- Randomized Phase 2 Study of Cabozantinib, Ipilimumab, and Nivolumab in Patients with Soft Tissue Sarcoma